LEO Pharma Taps Jörg Möller as EVP, Global Research and Development

Möller joins LEO Pharma from Bayer Pharma, where he has been EVP Head of R&D and Member of the Bayer Pharma Executive Committee.

Jörg Möller is joining LEO Pharma A/S’s Global Leadership Team as Executive Vice President (EVP), Global Research and Development, effective January 1, 2021.

Möller joins LEO Pharma from Bayer Pharma, where he has been EVP Head of R&D and Member of the Bayer Pharma Executive Committee.

A medical doctor and Ph.D. by training, Möller’s experience spans multiple therapeutic areas including dermatology and immunology and a variety of technology platforms like biologics and cell & gene therapies. He has a solid track record of working with external partners.

“Jörg Möller’s experience will help us to significantly foster our innovative pipeline which underpins our ambition to become a global leader in medical dermatology,” says Catherine Mazzacco, President and CEO of LEO Pharma, in a news release.

“I am excited to join LEO Pharma and inspired by its strategy and ambition. People with dermatologic medical conditions need new treatment options, and I want to bring in my experience and expertise to the R&D team at LEO Pharma so we together can contribute significantly to improving patients’ lives,” says Möller.

Möller succeeds Kim Kjøller who left LEO Pharma for a CEO role at Union Therapeutics.